Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax

NCT07407660 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

250

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Venetoclax
DRUG: Azacitidine (AZA)

Sponsor

Peking University People's Hospital

Collaborators

[object Object]